This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Ecolab's CoolIT Deal Raises AI Upside but Also Debt and Cost Risks
by Harshit Gupta
ECL's $4.75B CoolIT deal expands its AI data-center cooling opportunity, but higher debt and financing costs raise execution risks.
ECLPositive Net Change NVTNegative Net Change VRTNegative Net Change
medical medical-devices
Is Ecolab Stock Worth Buying as Growth Rises but Debt Risk Builds?
by Harshit Gupta
ECL's accelerating High-Tech, Digital and Life Sciences growth supports its outlook, but rising debt and financing costs keep the buy case cautious.
ECLPositive Net Change CLXNegative Net Change PNRNegative Net Change
medical medical-devices
Ecolab Rallies 12.2% in 3 Months as High-Tech Growth Gains Momentum
by Harshit Gupta
ECL's 12.2% three-month rally is backed by High-Tech, Digital and Life Sciences growth, firmer pricing and a higher 2026 earnings outlook.
ECLPositive Net Change PNRNegative Net Change STEPositive Net Change
medical medical-devices
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
by Ekta Bagri
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
GILDPositive Net Change GSKPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
COO Stock Surges 22% in Past Three Months: What's Driving the Uptrend?
by Zacks Equity Research
Cooper Companies' 22% three-month surge reflects contact lens share gains, MiSight growth and a recovering fertility business.
COOPositive Net Change BAXPositive Net Change ALCPositive Net Change BLCOPositive Net Change
medical medical-devices
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
by Zacks Equity Research
OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.
OPKNo Net Change CAHNegative Net Change MCKPositive Net Change PAHCPositive Net Change
medical medical-devices
Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery
by Zacks Equity Research
SNN launches the FLOW FLEXTEND COBLATION Wand, offering adjustable-angle access and precise tissue removal in complex joint procedures.
SNNPositive Net Change COOPositive Net Change WSTNegative Net Change GMEDPositive Net Change
medical medical-devices
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
by Zacks Equity Research
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
AZNPositive Net Change MRKNegative Net Change HCMPositive Net Change
biotechs medical pharmaceuticals
Can Corning's Next-Generation Glass Innovations Propel Its Shares?
by Zacks Equity Research
GLW's innovative glass portfolio spans Gorilla Glass, advanced display glass and specialty materials, positioning it to meet the growing tech demand.
GLWNegative Net Change ASGLYNegative Net Change OLEDNegative Net Change
auto-tires-trucks communications medical tech-stocks
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
by Zacks Equity Research
United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.
UTHRPositive Net Change RGENNegative Net Change ACIUPositive Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals